Publications

Add filters (0)

862 results

Viewing results for \"glomerular\"

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.

June 1, 2023

Lancet Gastroenterol Hepatol

Abstract BACKGROUND Alcohol is the leading cause of liver-related mortality worldwide. The gut-liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients with cirrhosis. We aimed to compare the efficacy and safety of rifaximin-α with placebo in patients with alcohol-related liver disease. METHODS GALA-RIF […]

Read publication

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

June 1, 2023

JHEP Rep

Abstract BACKGROUND & AIMS Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation to fibrosis progression and as a treatment efficacy marker. We investigated whether PRO-C3 was prognostic for clinical outcome and […]

Read publication

Novel fibro-inflammatory biomarkers associated with disease activity in patients with Crohn’s disease.

June 1, 2023

Expert Rev Gastroenterol Hepatol

Abstract INTRODUCTION Crohn’s disease (CD) is a complex disease, and assessing activity is challenging due to pathobiologic process e.g. ECM remodeling, mucosal damage, and intestinal fibrosis, which greatly limits current disease activity assessments through e.g. endoscopy and imaging techniques. AREAS COVERED The review highlights the importance of novel biomarkers reflecting ECM remodeling and immune cell […]

Read publication

Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis.

May 30, 2023

Int J Mol Sci

Abstract The association between structural changes and pain sensation in osteoarthritis (OA) remains unclear. Joint deterioration in OA leads to the release of protein fragments that can either systemically (serum) or locally (synovial fluid; SF) be targeted as biomarkers and describe structural changes and potentially pain. Biomarkers of collagen type I (C1M), type II (C2M), […]

Read publication

Lot-to-Lot Variance in Immunoassays-Causes, Consequences, and Solutions.

May 24, 2023

Diagnostics (Basel)

Abstract Immunoassays, which have gained popularity in clinical practice and modern biomedical research, play an increasingly important role in quantifying various analytes in biological samples. Despite their high sensitivity and specificity, as well as their ability to analyze multiple samples in a single run, immunoassays are plagued by the problem of lot-to-lot variance (LTLV). LTLV […]

Read publication

Endotrophin Levels Are Associated with Allograft Outcomes in Kidney Transplant Recipients.

May 5, 2023

Biomolecules

Abstract Early prediction of kidney graft function may assist clinical management, and for this, reliable non-invasive biomarkers are needed. We evaluated endotrophin (ETP), a novel non-invasive biomarker of collagen type VI formation, as a prognostic marker in kidney transplant recipients. ETP levels were measured with the PRO-C6 ELISA in the plasma (P-ETP) of 218 and […]

Read publication

Structural changes after ankle joint distraction in haemophilic arthropathy: an explorative study investigating biochemical markers and 3D joint space width.

May 1, 2023

Haemophilia

Abstract INTRODUCTION Ankle joint distraction (AJD) is a promising treatment for patients with severe haemophilic ankle arthropathy (HAA). However, some patients showed no clinical improvement after AJD and these differences may be related to structural differences. AIM Primarily to quantify the structural changes after AJD in patients with HAA by the use of 3D joint […]

Read publication

Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation.

April 13, 2023

Sci Rep

Abstract Detecting patients with early post-transplant fibrosis after liver transplantation (LT) is very important. Non-invasive tests are needed to avoid liver biopsies. We aimed to detect fibrosis in liver transplant recipients (LTR) using extracellular matrix (ECM) remodeling biomarkers. ECM biomarkers for type III (PRO-C3), IV (PRO-C4), VI (PRO-C6) and XVIII (PRO-C18L) collagen formation and type […]

Read publication

Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls.

April 11, 2023

Int J Mol Sci

Abstract Autoantibodies have the potential as cancer biomarkers as they may associate with the outcome and immune-related adverse events (irAEs) following immunotherapy. Cancer and other fibroinflammatory diseases, such as rheumatoid arthritis (RA), are associated with excessive collagen turnover leading to collagen triple helix unfolding and denaturation with exposure of immunodominant epitopes. In this study, we […]

Read publication

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.

April 1, 2023

JHEP Rep

Abstract BACKGROUND & AIMS FALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic steatohepatitis (NASH) and stage 3 fibrosis. This FALCON 1 analysis aimed to further assess the effect of pegbelfermin on NASH-related biomarkers, correlations between histological assessments and non-invasive biomarkers, and concordance between the week 24 histologically assessed primary endpoint […]

Read publication